Cullinan Therapeutics (CGEM) Interest Expenses (2020 - 2026)

Cullinan Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 833.22% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 833.22% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, down 92.16% from the prior year.
• Interest Expenses climbed to $2.8 million in Q1 2026 per CGEM's latest filing, from $9000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $130.9 million in Q4 2024 and bottomed at $9000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $3.1 million (2022), against an average of $17.7 million.
• Across the five-year window, Interest Expenses surged 901.6% in 2022 and slumped 99.99% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $46.8 million in 2022, then soared by 86.83% to $87.4 million in 2023, then jumped by 49.87% to $130.9 million in 2024, then slumped by 99.99% to $9000.0 in 2025, then jumped by 30488.89% to $2.8 million in 2026.
• Per Business Quant, the three latest CGEM Interest Expenses figures stand at $2.8 million (Q1 2026), $9000.0 (Q4 2025), and $1.2 million (Q3 2025).